Revolution Medicines has set the annual list price for its new pancreatic cancer treatment at approximately $480,000, equating to $663 per tablet. This pricing reflects a broader trend in the oncology drug market, where annual costs frequently exceed several hundred thousand dollars.

The company’s pricing follows the pattern established by recent cancer therapies, including CAR-T treatments priced between $550,000 and $600,000 per single infusion. Other oral cancer medications also command prices in the upper hundreds of thousands annually. For instance, a gastrointestinal cancer pill is listed at $520,000 a year, while a leukemia drug taken twice daily carries a price tag of $430,000 annually.

In 2024, nine cancer drugs entered the market with sticker prices surpassing $400,000 per year, according to data from the Institute for Clinical and Economic Review (ICER), an independent organization that assesses drug value. This trend represents a notable shift compared to two decades ago when cancer drug prices above $100,000 annually were met with widespread scrutiny and debate.

The rising costs have been largely driven by pharmaceutical companies’ pricing strategies, set primarily according to market tolerance rather than stringent regulatory limits. These high prices impact multiple payers, including government healthcare programs and private insurers, which often shift the financial burden to employers and patients through higher premiums, co-pays, and other out-of-pocket expenses.

Experts and advocates continue to debate the sustainability and fairness of such pricing levels, as innovation in cancer treatment advances alongside increasing challenges related to accessibility and affordability.